A Proteomic Approach Identifies Novel Proteins Involved in Invasion Mechanisms in Enteroendocrine Carcinomas Abstract #204

Introduction: Enteroendocrine tumors dramatically lack reliable biomarkers to accurately select therapeutic strategy, due to a poor knowledge of molecular mechanisms leading to local invasion and dissemination.
Aim(s): To identify novel proteins involved in the acquisition of the invasive phenotype, defining the malignant behavior of the tumor.
Materials and methods: We used an original orthotopic xenograft model reproducing local invasion and metastatic dissemination. We compared the protein expression pattern at two stages of tumor development: non-invasive and invasive stage, through a proteomic analysis followed by validation in mouse tumors, as well as in human enteroendocrine carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Colette Roche

To read results and conclusion, please login ...

Further abstracts you may be interested in

#117 Synchronous appendiceal neuroendocrine carcinoma and mucinous cystadenocarcinoma: a case report
Introduction: Appendiceal tumors with histological features of both carcinoids and adenocarcinomas are very rare. Carcinomas of the appendix are usually mucinous adenocarcinomas with a tendency to produce peritoneal pseudomyxoma and without metastatic spread until late in the disease course. Carcinoid tumors of the appendix are a common incidental finding.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
#602 Antitumoral Effect of Everolimus in Preclinical Models of Poorly Differentiated Neuroendocrine Carcinomas
Introduction: For the small and large cells poorly differentiated neuroendocrine carcinomas (PDNECs) emergency treatment remains the combination cisplatin/etoposide. However, recent studies suggest that targeted therapies could be a therapeutic option for this group of highly aggressive carcinomas.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Colette Roche
Authors: Bollard J, Couderc C, Blanc M, Poncet G, ...
#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET
Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Jerome Cros
Authors: Bucau M, Cros J, Raffenne J, Rebours V, ...
#1168 Simultaneous Large Cell Neuroendocrine Carcinoma and Adenocarcinoma of the Stomach: A Case Report and Literature Review
Introduction: Large cell neuroendocrine carcinoma (LCNEC) of the stomach is rare. Gastric NEC occasionally has another component, such as adenocarcinoma, in the same tumor. However, the concurrent occurrence of LCNEC and adenocarcinoma at different sites in the stomach is extremely rare.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Shoichi Nakazuru
#1400 Versatile Goblet Cell Carcinoma of the Appendix - A Case Presentation
Introduction: Goblet cell carcinoma of the appendix is a rare tumor that can be classified as a subtype of mixed adeno-neuroendocrine carcinomas.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: MD Ioana Maria Lambrescu